How About Actinium-225? 🚨 #SNMMI25 Highlights: Dr. Machaba Sathekge University of Pretoria calls #Actinium225 “the world’s rarest drug” — and it's gaining major ground in advanced #ProstateCancer treatment. 🔬 Potent α-emissions 📈 Market to hit $1.8B by 2031 🧬 PSA declines ≥90% seen in

The Role of Histogram-Based Textural Analysis of 18F-FDG PET/CT in Evaluating Tumor Heterogeneity and Predicting the Prognosis of Invasive Lung Adenocarcinoma You can see the free full text of the research by Hasan Önner et al. Link : mirt.tsnmjournals.org/articles/the-r…

Danish data show better survival with salvage RT in the PSMA PET/CT era. jnm.snmjournals.org/content/early/… SNMMI

Does race impact outcomes to LuPSMA? A multi-institutional retrospective study (N=650) found no significant differences in PSA response or overall survival across racial groups in mCRPC Praful Ravi

Gallium spots, Lutetium hits. Harmony.

Ga shows you the path, Lu walks it.

Global problems need global minds.

Impressive lineup. From PSMA to PROTACs, the field is moving fast. Each trial is reshaping what frontline and beyond could mean. Lots to watch in the coming years.

According to real-world data, using advanced imaging before salvage radiotherapy improves survival in recurrent prostate cancer. Discover findings on EMJ: hubs.ly/Q03tNQhz0

✅ Read a #blog summary about this #research paper #published in Volume 15: "Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN." #Summary ⬇️ oncotarget.org/2024/07/11/ai-… #cancer #AI #prostatecancer

Superscan Appearance of 68Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer You can see the free full text of the research by Zehra Pınar Koç et al. Link : mirt.tsnmjournals.org/articles/super… #PSMA #prostate #cancer

Have really enjoyed recruiting into this trial and looking forward to the readout. Maybe #eau26??

¹⁸F-CTT1057 is effective in detecting PSMA-positive lesions, with high patient-level sensitivity and region-level specificity. ow.ly/uBa150W9YBZ #NuclearMedicine #MolecularImaging #ProstateCancer prof. Stefano Fanti Francesco Ceci Nicolò Buffi Pilar Paredes

"Can we kill the bone scan?" Bone scans lack sensitivity vs PSMA PET and no longer serve any role in prostate cancer staging or diagnosis!! — Dr. Spratt (Daniel E Spratt) | #PSMAandBeyond2025

Big step for Tb-161. Safe, well-tolerated, delivered fast. Auger era begins.

#ACCEL trial tests actinium-225-PSMA-62 in #ProstateCancer. Ramy Saleh, MD, MSc Research Institute of the MUHC (The Institute) joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss on UroToday. Early results show reduced xerostomia & minimal toxicity—potentially expanding radioligand options beyond Lu-177. #FullVideo >

Congrats to Nuc Med Technologist/CT Hybrid Tori West for winning 1st Place Technologist Best Poster at the SNMMI Annual Meeting! Her abstract, "Variability in Clinical Practice of Lutetium-177 Therapies," highlights important work in advancing nuclear medicine practices.

Exploring actinium-225 in PSMA-targeted therapy for #ProstateCancer. Michael Morris, MD Memorial Sloan Kettering Cancer Center, joins Oliver Sartor, MD Mayo Clinic in this discussion highlighting the CONV01-Alpha trial, which is exploring dose optimization in both pre-Pluvicto and post-Pluvicto

Important topic. Post-Lu-PSMA treatment decisions in mCRPC still lack standardization.

Impressive OS benefit with manageable toxicity. +8 months and better QoL is hard to ignore. ENZA-p pushes combo RLT into real-world relevance. Curious how it will shape guidelines.